-transparent.png){kind=logo}
1. The combined use of alpha-methyldopa and L-alpha-methyldopa hydrazine (a peripheral decarboxylase inhibitor) has been studied, in a double-blind cross-over comparison, with alpha-methyldopa and L-alpha-methyldopa hydrazine placebo in the treatment of eight patients with essential hypertension. 2. L-alpha-methyldopa hydrazine did not enhance the antihypertensive effect of alpha-methyldopa. This suggests that because methyldopa can inhibit its own decarboxylation, peripheral decarboxylation is not an important metabolic pathway for methyldopa and elevated brain levels of methyldopa do not necessarily result in elevated brain levels of methyldopamine.
Related Publications
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
August 1974,
Australian and New Zealand journal of medicine,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
January 1973,
Confinia neurologica,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
May 1981,
La Clinica terapeutica,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
August 1965,
Die Medizinische Welt,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
August 1975,
La Clinica terapeutica,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
February 1965,
Schweizerische medizinische Wochenschrift,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
March 1976,
Ceskoslovenska neurologie a neurochirurgie,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
December 1962,
El Dia medico,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
May 1964,
The Medical journal of Australia,
W J Louis, and
F J Vajda, and
J J McNeil, and
A E Doyle, and
B Jarrott
March 1964,
The Medical clinics of North America,
